The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to commercialization in the rest of the world.

The companies plan to create a treatment combining Roche’s GLP-1 asset, CT-388, with Zealand Pharma’s amylin analog.

Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced last year. A phase 1b trial ...

Carmot’s pipeline includes three clinical-stage programmes, headed by CT-388, a dual GLP-1/GIP agonist – in the same class as Eli Lilly’s tirzepatide-based Mounjaro and Zepbound products for ...

In addition, the combination of petrelintide with Roche’s dual GLP-1/GIP receptor agonist CT-388 will further strengthen and expand Roche’s pipeline in the field of cardiovascular, renal ...

Why it matters: Roche entered the obesity landscape with the $2.7 billion acquisition of Carmot in early 2024, giving the firm access to development-stage candidates, including CT-388 and oral ...

Roche and Zealand Pharma have entered into a partnership worth up to $5.3bn to advance Zealand’s mid-stage obesity candidate petrelintide.